Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Pharma's 'Brexit Playbook' Might Envision New Regulator Roles

Executive Summary

Britain's life sciences sector is compiling detailed game plan for September talks with the new Conservative government to promote its interests once the UK leaves the EU. All options are being considered – including possible establishment of a best-in-class regulatory agency in Britain.

You may also be interested in...



AstraZeneca’s Business Development Head Grady Outlines Strategy Mix

AstraZeneca’s total focus on its core therapy areas will ensure it keeps building external collaborations and doing deals to generate new therapies while maximizing revenues, but outright sales of non-core mature medicines are likely to be fewer going forward, according to the company’s head of business development.

Strong 2Q And Fresh UK Investment Signal Few Brexit Blues at GSK

GlaxoSmithKline reported a strong second quarter and along with its core EPS guidance upgrade, this adds momentum to its post-Brexit vote boost.

George Freeman Departure Leaves UK Life Sciences Holding Its Breath

Theresa May has re-structured the Department of Health ministerial team as part of her wide-ranging reshuffle and in so doing moved life sciences minister George Freeman over to chair the prime minister’s policy board. The British biopharma community says it hopes he will be replaced – and soon.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142639

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel